Cell therapy developer Adaptimmune announced the sale of its sarcoma therapy Tecelra and two late-stage assets to US WorldMeds for an upfront payment of $55 million, with potential $30 million in milestones. The deal includes transferring employees involved with these assets and follows recent workforce reductions totaling over 60%. Despite Tecelra’s FDA accelerated approval and the innovative TCR technology, the company has struggled with low revenues and high R&D expenses. Adaptimmune will retain early-stage T cell therapies and aims to stabilize its financial position through this transaction.